ArticlePharmaceuticals (Basel, Switzerland)2022

Repurposing Lenvatinib as A Potential Therapeutic Agent against Thyroid Eye Disease by Suppressing Adipogenesis in Orbital Adipose Tissues.

Lu Cheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.